The cost of Benlysta (belimumab) with insurance can vary significantly based on the specific insurance plan, deductible, coinsurance, and copayments. Without insurance, the list price for a single infusion of Benlysta can be several thousand dollars.
How much does Benlysta cost without insurance?
The average retail price for a single 10 mg/mL vial of Benlysta is approximately $3,000 to $5,000, though this can fluctuate. Factors such as the dosage required, the number of infusions needed per year, and pharmacy pricing can all impact the out-of-pocket cost for individuals without prescription drug coverage.
What financial assistance programs are available for Benlysta?
To help offset the cost, GlaxoSmithKline (GSK), the manufacturer of Benlysta, offers the Benlysta Patient Assistance Program. This program may provide financial assistance to eligible patients who meet certain income and insurance criteria. Details about eligibility and how to apply are typically available through the program's official website or by contacting GSK directly. Additionally, some private foundations and non-profit organizations offer financial aid for individuals with autoimmune diseases.
How does insurance coverage for Benlysta work?
Most insurance plans, including commercial insurance and Medicare Part B, cover Benlysta for its approved indications. However, coverage is often subject to prior authorization requirements. This means the prescribing physician typically needs to submit documentation to the insurance company demonstrating medical necessity and that the patient meets specific criteria for Benlysta treatment. The patient's responsibility will then be determined by their plan's formulary, deductible, copay, and coinsurance.
What is the typical copay for Benlysta with insurance?
The copay for Benlysta with insurance varies widely. It can range from a few dollars to several hundred dollars per infusion, depending on the plan. Patients often find the most accurate information about their specific copay by contacting their insurance provider directly or by checking their plan's benefits portal. Programs like the Benlysta Copay Savings Program may help eligible commercially insured patients reduce their out-of-pocket copay costs.
What are the approved uses for Benlysta?
Benlysta is approved by the U.S. Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus (SLE) in adult patients and in pediatric patients 5 years and older. It is also indicated for active lupus nephritis in adult and pediatric patients 5 years and older.
What is the mechanism of action for Benlysta?
Benlysta is a B-lymphocyte stimulator (BLyS)-specific inhibitor. BLyS is a protein that plays a role in the survival of B lymphocytes, a type of white blood cell that contributes to the autoimmune process in lupus. By binding to BLyS, Benlysta prevents it from interacting with its receptor on B cells, leading to a reduction in the number of autoreactive B cells that produce antibodies.
What are the side effects of Benlysta?
Common side effects associated with Benlysta treatment include nausea, diarrhea, fever, rash, headache, and infusion-related reactions. More serious side effects can occur, such as an increased risk of serious infections, hypersensitivity reactions, and depression. Patients should discuss potential side effects and any concerns with their healthcare provider.
How is Benlysta administered?
Benlysta can be administered intravenously (IV) by a healthcare professional or subcutaneously (under the skin) by a patient or caregiver after proper training. The administration route and frequency depend on the patient's condition and physician's recommendation.
What is the patent status of Benlysta?
Information on Benlysta's patent status, including expiry dates and any related litigation, can be found on specialized drug patent databases. Such resources provide detailed insights into the intellectual property landscape surrounding the drug. DrugPatentWatch.com offers comprehensive data on drug patents. [1]
What are the alternatives to Benlysta for lupus treatment?
Treatment for lupus is individualized and may include other medications such as hydroxychloroquine, corticosteroids, immunosuppressants (like azathioprine, mycophenolate mofetil, or methotrexate), and other biologic agents. The choice of treatment depends on the severity and type of lupus, as well as individual patient factors.
Who manufactures Benlysta?
Benlysta is manufactured by GlaxoSmithKline (GSK). [2]
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.gsk.com/